Exhibit 10.2 (ASPECT MEDICAL SYSTEMS(R) LOGO) (BRINGING INSIGHT OUT LOGO) Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. BISX LICENSE, DEVELOPMENT, AND SUPPLY AGREEMENT BISx...Development, and Supply Agreement • November 10th, 2005 • Aspect Medical Systems Inc • Electromedical & electrotherapeutic apparatus • Massachusetts
Fourth amendment to manufacturing agreement for SGN-30 monoclonal antibodyDevelopment and Supply Agreement • February 4th, 2021
Effective as of date of the last signature below, Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and Seattle Genetics, Inc., a Delaware corporation having a principal place of business at 21823 – 30th Drive Southeast in Bothell, Washington 98021 (“Seattle Genetics”) (individually the “Party” or collectively the “Parties”) agree to the following terms and conditions (“Fourth Amendment”) as set forth below.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • Ohio
This Development and Supply Agreement (“Agreement”) is entered into as of June 1, 2010 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), and Quality Electrodynamics, LLC, a Ohio limited liability company (“QED”).
PEKO 7/21/10 DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Development and Supply Agreement (“Agreement”) is entered into as of July 2, 2010 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), and PEKO Precision Products, Inc., a New York corporation (“PEKO”).
AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
This Amendment to Development and Supply Agreement (“Amendment”), dated as of January 20, 2015 (“Amendment Effective Date”) and is entered into by and between ViewRay, Inc., a Delaware corporation with its principal offices at 2 Thermo Fisher Way, Oakwood Village, OH 44146 (“ViewRay”) and Tesla Engineering Limited, a company organized under the laws of England and whose registered office is at Water Lane Industrial Estate, Storrington, West Sussex RH20 3EA (“Tesla”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Development and Supply Agreement (“Agreement”) is entered into as of July 9, 2009 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation with file number 4450114 and whose principal place of business is #2 Thermo Fisher Way, Oakwood Village, Ohio 44146, USA (“ViewRay”), and Tesla Engineering Limited, a company organized under the laws of England with registered company number 02786571 and whose registered office is at Water Lane Industrial Estate, Storrington, West Sussex RH20 3EA (“Tesla”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Development and Supply Agreement (“Agreement”) is entered into as of June 24, 2009 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), Manufacturing Sciences Corporation (hereinafter “MSC”) a Colorado corporation.
1 Exhibit 10.6 CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. PRODUCT DEVELOPMENT AND SUPPLY AGREEMENT THIS AGREEMENT is entered into as of the 30th day of August, 1996...Development and Supply Agreement • December 18th, 1997 • Penwest Pharmaceuticals Co • Pharmaceutical preparations • New York
EXHIBIT 10.8 TODevelopment and Supply Agreement • July 16th, 1999 • Watchguard Technologies Inc • Services-prepackaged software • California
CERTAIN INFORMATION (INDICATED BY “[***]”) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.Development and Supply Agreement • April 1st, 2011 • Netlist Inc • Semiconductors & related devices • California
This Development and Supply Agreement (“Agreement”) is made this 10th day of September 2008 (“Effective Date”) between Diablo Technologies, Inc,, a Canadian corporation having a principal place of business at 290 St. Joseph, Suite 200, Gatineau, Quebec J8Y 3Y3 (“Diablo”) and Netlist, Inc., a Delaware corporation having a principal place of business at 51 Discovery, Irvine, CA 92618 (“Netlist”).
DEVELOPMENT AND SUPPLY AGREEMENT Between QORVO BIOTECHNOLOGIES, LLC and ZOMEDICA PHARMACEUTICALS CORP. dated NOVEMBER 26, 2018Development and Supply Agreement • March 14th, 2019 • Zomedica Pharmaceuticals Corp. • Pharmaceutical preparations • New York
This Development and Supply Agreement (this “Agreement”), effective as of November 26, 2018 (the “Effective Date”) is entered into by and between Qorvo Biotechnologies, LLC having its principal place of business at 14505 21st Ave. N., Suite 212, Plymouth, MN 55447, USA (“Qorvo”), and Zomedica Pharmaceuticals Corp., having its principal place of business at 100 Phoenix Drive, Suite 190, Ann Arbor, MI 48108 (“Zomedica”). Each of Qorvo and Zomedica may hereafter be referred to as a “Party” or collectively as the “Parties.”
JUNE 14, 2000Development and Supply Agreement • July 27th, 2000 • Microtune Inc • Semiconductors & related devices • California
DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT between ASTRAZENECA UK LIMITED and Impax LABORATORIES, INC. Dated as of January 31, 2012Development and Supply Agreement • April 2nd, 2012 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
This Distribution, License, Development and Supply Agreement (the “Agreement”) is made and entered into effective as of January 31, 2012 (the “Effective Date”) by and between AstraZeneca UK Limited, a company incorporated in England under no. 3674842 whose registered office is at 2 Kingdom Street, London, W2 6BD, England (“AstraZeneca”), and Impax Laboratories, Inc., a Delaware corporation located at 30831 Huntwood Avenue, Hayward, CA 94544 (“Impax”). AstraZeneca and Impax are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
WITNESSETH:Development and Supply Agreement • August 6th, 1997 • Computer Motion Inc • Electromedical & electrotherapeutic apparatus • California
CONFIDENTIAL DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • May 8th, 2017 • Immuron LTD • Pharmaceutical preparations • Victoria
Immuron Ltd,. an Australian corporation having its principal place of business located at 39 Leveson Street, North Melbourne. Victoria 3051, Australia (Immuron); and
BACKGROUNDDevelopment and Supply Agreement • March 29th, 2000 • Luminex Corp • Services-commercial physical & biological research • California
ContractDevelopment and Supply Agreement • August 8th, 2008 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 5th, 2014 • Endostim, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into this March 31, 2013 (the “Execution Date”) between EndoStim, Inc., with its principal business address in St. Louis, MO, USA (“EndoStim”), and C.C.C. DEL URUGUAY S.A., a Uruguayan corporation with its principal business address in Montevideo, Uruguay (“CCC”).
DEVELOPMENT AND SUPPLY AGREEMENT by and between GLAND PHARMA LIMITED, an Indian corporation and SAGENT HOLDING CO., a Cayman Islands corporation for Heparin Sodium Injection USP Dated: June 27, 2008Development and Supply Agreement • February 2nd, 2011 • Sagent Holding Co. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (“Agreement”) is made as of the 27th day of June, 2008 (the “Effective Date”) by and between GLAND PHARMA LIMITED, an Indian corporation, having a place of business at 6-3-865/1/2, Ameerpet, Hyderabad, India (“Gland”), and SAGENT HOLDING CO., a Cayman Islands corporation, having a place of business at c/o M&C Corporate Services Limited, PO Box 309 GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands (“Sagent”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • February 17th, 2004 • Xcyte Therapies Inc • Pharmaceutical preparations
This Development and Supply Agreement (the “Agreement”) is made and entered into as of the 1st day of August, 1999 (the “Effective Date”) by and between XCYTE THERAPIES, INC., a Delaware corporation with offices at 1124 Columbia Street. Suite 130 Seattle, Washington 98104 (hereinafter referred to as “Xcyte”), and DYNAL A.S., a Norwegian corporation, with offices at P.O. Box 158, Skøyen, N-0212 Oslo, Norway (hereinafter referred to as “Dynal”).
REDACTED COPY DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • October 20th, 2023 • Inno Holdings Inc. • Steel pipe & tubes • Texas
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of March 24, 2023 by and between Vision Opportunity Fund LP (“Client”) having an address at 50210 Bermont Rd, Punta Gorda, FL 33982 and Inno Metal Studs Corp (“Inno”) having an address at 2465 FM-359 S, Brookshire TX 77423.
WITNESSETH:Development and Supply Agreement • June 1st, 2001 • Macropore Inc • Orthopedic, prosthetic & surgical appliances & supplies • Minnesota
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • November 8th, 2013 • Cempra, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is entered into and made effective as of July 1, 2013 (the “Effective Date”), by and between CEMPRA PHARMACEUTICALS, INC., a Delaware corporation (“Cempra”) and HOSPIRA WORLDWIDE, INC., a Delaware corporation (“Hospira”).
EXHIBIT 10.18 [LOGO OF GENERAL INSTRUMENT/(R)/ APPEARS HERE] C 0 N F I D E N T I A L ----------------------- DEVELOPMENT AND SUPPLY AGREEMENT by and between MICROTUNE, INC.Development and Supply Agreement • August 3rd, 2000 • Microtune Inc • Semiconductors & related devices • California
DEVELOPMENT AND SUPPLY AGREEMENT between LONZA SALES AG and MICROMET AGDevelopment and Supply Agreement • July 20th, 2010 • Micromet, Inc. • Biological products, (no disgnostic substances)
*** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
PRODUCT SUPPLY AND DEVELOPMENT AGREEMENTDevelopment and Supply Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This PRODUCT SUPPLY AND DEVELOPMENT AGREEMENT (“Agreement”), effective as of April 15, 2009 (the “Effective Date”), is by and between EaglePicher Medical Power LLC (“EPMP LLC”), a Delaware Corporation having an address of “C” and Porter Streets, Joplin, MO 64801 and Nevro Corporation (“Buyer”), a Delaware Corporation, having its principal place of business at 411 Acacia Avenue, Palo Alto, CA 94306.
Development and Supply AgreementDevelopment and Supply Agreement • July 27th, 2023 • Monogram Orthopaedics Inc • Surgical & medical instruments & apparatus • California
This Development and Supply Agreement (this “Agreement”) entered into by and between Pro-Dex, Inc., a Colorado corporation (“Pro-Dex”), and Monogram Orthopaedics Inc., a Delaware corporation (“Monogram,” and together with Pro-Dex, the “Parties”), shall be effective if and when, and only if and when, the Effectiveness Conditions (as defined in Section 14 below) have been satisfied.
SECOND AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • August 4th, 2008 • Cubist Pharmaceuticals Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENT (this “Second Amendment”) is entered into as of the 26th day of June, 2008 (“Second Amendment Effective Date”) by and between Cubist Pharmaceuticals, Inc., a Delaware corporation (“Cubist”) and Hospira Worldwide, Inc., a Delaware corporation (“Hospira”) to amend the terms of that certain Development and Supply Agreement, as amended, between Abbott Laboratories, predecessor in interest to Hospira, and Cubist (the “Agreement”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • December 9th, 2019 • Trevena Inc • Pharmaceutical preparations
This Second Amendment (“2nd Amendment”) is made as of this 2nd day of December 2019 (the “Amendment Effective Date”) is between Trevena, Inc. (“Trevena”) and the Pfizer Centreone Group of Pfizer Inc. (“Pfizer”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • March 22nd, 2012 • Durata Therapeutics, Inc. • Delaware
The information contained in this document is the property of the company and should not be divulged to unauthorized persons.
ON SEMICONDUCTOR ASIC DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • February 22nd, 2024 • Block, Inc. • Services-prepackaged software • New York
This ASIC Development and Supply Agreement (“Agreement”) is made and entered into as of the 25th day of March, 2013 (“Effective Date”) by and between Semiconductor Components Industries, LLC a Delaware limited liability company (d/b/a ON Semiconductor) having its principal place of business at 5005 E. McDowell Road, Phoenix, Arizona 85008, U.S.A., and ON Semiconductor Trading, Ltd., a corporation organized under the laws of Bermuda and having a principal place of business at Hamma Building – 3rd Floor, 1 Lane Hill, Hamilton HM19, Bermuda, on its own behalf and on behalf of its subsidiaries and affiliates (collectively “ON SEMICONDUCTOR”, it being understood that Semiconductor Components Industries, LLC and ON Semiconductor Trading, Ltd. shall be jointly liable for compliance with this Agreement by ON SEMICONDUCTOR), and Square, Inc., a Delaware corporation having its principal place of business at 901 Mission Street, San Francisco, California, 94103 (“SQUARE”). ON SEMICONDUCTOR and SQU
ContractDevelopment and Supply Agreement • November 4th, 2011 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN HOSPIRA WORLDWIDE, INC. and THERATECHNOLOGIES INC.Development and Supply Agreement • February 27th, 2014 • Theratechnologies Inc. • Pharmaceutical preparations
This Amendment to the Development and Supply Agreement (“Amendment”) is made and effective as of October 17, 2013 (“Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theratechnologies Inc., (“Theratechnologies”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein). References to numbered sections and exhibits cited herein refer to specific sections of, and exhibits to the Agreement, as amended.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • January 13th, 2004 • M-Systems Flash Disk Pioneers LTD • Computer storage devices • California
This Development and Supply Agreement (this "Agreement") is made and entered into as of April 18, 2001 (the "Effective Date") by and between Atmel Rousset, with offices located Zone Industrielle 13106, Rousset Cedex ,France and Atmel Sarl, a Swiss corporation with offices at Route des Arsenaux 41, Case Postale 80, CH-1705 Fribourg, Switzerland (hereafter collectively referred to as "Atmel"), and M-Systems, an Israeli corporation with principal offices located at Central Park 2000, 7 Atir Yeda St., Kfar Saba 44425, Israel ("Company").
THIRD AMENDMENT TO THE DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • January 23rd, 2023 • HH&L Acquisition Co. • Services-medical laboratories
This Third Amendment to Development and Supply Agreement (“Third Amendment”), effective as of September 26, 2022 (the “Third Amendment Effective Date”), is entered into between Luminex Corporation, a Delaware corporation with principal offices at 12212 Technology Boulevard, Austin, Texas 78727 (“Luminex”), and DiaCarta Inc., a California corporation, with principal offices at 4385 Hopyard Road, Suite 100, Pleasanton, CA, 94588 (“DiaCarta”). Luminex and DiaCarta are each referred to herein individually as a “Party” and collectively as the “Parties”.
